Biomarkers of Nonalcoholic Fatty Liver Disease in Obese Patients
Author Information
Author(s): Julia Kälsch, Lars P. Bechmann, Hagen Kälsch, Martin Schlattjan, Jochen Erhard, Guido Gerken, Ali Canbay
Primary Institution: University Hospital Essen
Hypothesis
Caspase-cleaved cytokeratin 18 can serve as a biomarker for diagnosing fibrosis in morbidly obese patients with NAFLD.
Conclusion
Caspase-cleaved CK18 levels correlate with liver steatosis and hepatocyte apoptosis, suggesting its potential as a noninvasive biomarker for NAFLD diagnosis.
Supporting Evidence
- Caspase-cleaved CK18 levels were higher in patients with NASH compared to those with simple steatosis.
- Serum hyaluronic acid levels correlated with the extent of fibrosis in NAFLD patients.
- Patients with advanced fibrosis had significantly higher levels of M30, a marker for hepatocyte apoptosis.
Takeaway
Doctors can use a blood test to check for a specific protein that helps them understand liver damage in very overweight patients.
Methodology
The study evaluated caspase-cleaved CK18 and hyaluronic acid as biomarkers for NAFLD and fibrosis in morbidly obese patients undergoing bariatric surgery.
Limitations
The study's findings may not be generalizable to non-obese populations, and further validation of biomarkers is needed.
Participant Demographics
127 morbidly obese patients (mean age: 45, 78.7% females, mean BMI: 52) and a control group of 10 healthy volunteers.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website